Trial Profile
Phase I trial of CC 359
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I
Latest Information Update: 29 May 2020
Price :
$35
*
At a glance
- Drugs CC 359 (Primary)
- Indications Reperfusion injury
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 20 Jul 2007 New trial record.